High MAL2 expression predicts shorter survival in women with triple-negative breast cancer.
Biomarker
Breast cancer
MAL2
PD-L1
Prognosis
Survival
Triple-negative
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
20 May 2024
20 May 2024
Historique:
received:
03
03
2024
accepted:
03
05
2024
medline:
21
5
2024
pubmed:
21
5
2024
entrez:
20
5
2024
Statut:
aheadofprint
Résumé
Due to its lack of conventional surface receptors, triple-negative breast cancer (TNBC) is inherently resistant to most targeted therapies. MAL2 overexpression prompts endocytosis, conferring resistance to novel therapeutics. This study explores the role of MAL2 and PD-L1 in TNBC patients' prognosis. We performed immunohistochemical analysis on 111 TNBC samples collected from 76 patients and evaluated the expression of MAL2 and PD-1. We expanded the study by including The Cancer Genome Atlas (TCGA) cohort. MAL2 expression did not correlate with stage, grade, tumor size, lymph node invasion, metastasis, and PD-1 expression. Patients with high MAL2 had significantly lower 5-year survival rates (71.33% vs. 89.59%, p = 0.0224). In the tissue microarray cohort (TMA), node invasions, size, recurrence, and low MAL2 (HR 0.29 [CI 95% 0.087-0.95]; p < 0.05) predicted longer patients' survival. In the TCGA cohort, patients with low MAL2 had significantly longer overall survival and disease-specific survival than patients with high MAL2. Older age and high MAL2 expression were the only independent predictors of shorter patient survival in the BRCA TCGA cohort. High MAL2 predicts unfavorable prognosis in triple-negative breast cancer, and its expression is independent of PD-1 levels and clinicopathological features of TNBC.
Identifiants
pubmed: 38769215
doi: 10.1007/s12094-024-03514-4
pii: 10.1007/s12094-024-03514-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Breast cancer. [cited 17 May 2023]. Available: https://www.who.int/news-room/fact-sheets/detail/breast-cancer . Accessed 24 Apr 2024.
Triple-negative breast cancer. [cited 3 May 2023]. Available: https://www.cancer.org/cancer/breast-cancer/about/types-of-breast-cancer/triple-negative.html . Accessed 24 Apr 2024.
Irvin WJ Jr, Carey LA. What is triple-negative breast cancer? Eur J Cancer. 2008;44:2799–805. https://doi.org/10.1016/j.ejca.2008.09.034 .
doi: 10.1016/j.ejca.2008.09.034
pubmed: 19008097
Smolarz B, Nowak AZ, Romanowicz H. Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature). Cancers. 2022. https://doi.org/10.3390/cancers14102569 .
doi: 10.3390/cancers14102569
pubmed: 35626173
pmcid: 9139759
Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106–16. https://doi.org/10.7497/j.issn.2095-3941.2015.0030 .
doi: 10.7497/j.issn.2095-3941.2015.0030
pubmed: 26175926
pmcid: 4493381
Li Y, Zhan Z, Yin X, Fu S, Deng X. Targeted therapeutic strategies for triple-negative breast cancer. Front Oncol. 2021;11: 731535. https://doi.org/10.3389/fonc.2021.731535 .
doi: 10.3389/fonc.2021.731535
pubmed: 34778045
pmcid: 8581040
Zhong Y, Zhuang Z, Mo P, Shang Q, Lin M, Gong J, et al. Overexpression of MAL2 correlates with immune infiltration and poor prognosis in breast cancer. Evid Based Complement Alternat Med. 2021;2021:5557873. https://doi.org/10.1155/2021/5557873 .
doi: 10.1155/2021/5557873
pubmed: 34567213
pmcid: 8457941
Dersh D, Yewdell JW. Immune MAL2-practice: breast cancer immunoevasion via MHC class I degradation. J Clin Invest. 2021. https://doi.org/10.1172/jci144344 .
doi: 10.1172/jci144344
pubmed: 33393509
pmcid: 7773378
Fang Y, Wang L, Wan C, Sun Y, Van der Jeught K, Zhou Z, et al. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. J Clin Invest. 2021. https://doi.org/10.1172/jci140837 .
doi: 10.1172/jci140837
pubmed: 34779411
pmcid: 8592536
Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, et al. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer. 2010;10:497. https://doi.org/10.1186/1471-2407-10-497 .
doi: 10.1186/1471-2407-10-497
pubmed: 20846453
pmcid: 2949808
Yuan J, Jiang X, Lan H, Zhang X, Ding T, Yang F, et al. Multi-omics analysis of the therapeutic value of MAL2 based on data mining in human cancers. Front Cell Dev Biol. 2021;9: 736649. https://doi.org/10.3389/fcell.2021.736649 .
doi: 10.3389/fcell.2021.736649
pubmed: 35111745
Schütz F, Stefanovic S, Mayer L, von Au A, Domschke C, Sohn C. PD-1/PD-L1 pathway in breast cancer. Oncol Res Treat. 2017;40:294–7. https://doi.org/10.1159/000464353 .
doi: 10.1159/000464353
pubmed: 28346916
Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020;11:955. https://doi.org/10.1038/s41419-020-03140-2 .
doi: 10.1038/s41419-020-03140-2
pubmed: 33159034
pmcid: 7648632
Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361–70. https://doi.org/10.1158/2326-6066.cir-13-0127 .
doi: 10.1158/2326-6066.cir-13-0127
pubmed: 24764583
pmcid: 4000553
Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance mechanisms of anti-PD1/PDL1 therapy in solid tumors. Front Cell Dev Biol. 2020;8:672. https://doi.org/10.3389/fcell.2020.00672 .
doi: 10.3389/fcell.2020.00672
pubmed: 32793604
pmcid: 7385189
Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217–26. https://doi.org/10.1056/nejmoa2202809 .
doi: 10.1056/nejmoa2202809
pubmed: 35857659
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32:994–1004. https://doi.org/10.1016/j.annonc.2021.05.801 .
doi: 10.1016/j.annonc.2021.05.801
pubmed: 34219000
Ventana Medical Systems, Inc. and Roche Diagnostics International, Inc. Ventana PD-L1 (SP142) assay quick referene guide for ttiple-negative breast carcinoma (TNBC). 2022. Available: https://elabdoc-prod.roche.com/eLD/api/downloads/dba77a2d-da62-ea11-fa90-005056a772fd?countryIsoCode=be . Accessed 24 Apr 2024.
Nicholson RI, Bouzubar N, Walker KJ, McClelland R, Dixon AR, Robertson JF, et al. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer. 1991;27:908–13. https://doi.org/10.1016/0277-5379(91)90145-4 .
doi: 10.1016/0277-5379(91)90145-4
pubmed: 1834127
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4. https://doi.org/10.1158/2159-8290.cd-12-0095 .
doi: 10.1158/2159-8290.cd-12-0095
pubmed: 22588877
Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38:675–8. https://doi.org/10.1038/s41587-020-0546-8 .
doi: 10.1038/s41587-020-0546-8
pubmed: 32444850
pmcid: 7386072
Expression of MAL2 in breast cancer - the human protein atlas. [cited 26 Jan 2023]. Available: https://www.proteinatlas.org/ENSG00000147676-MAL2/pathology/breast+cancer . Accessed 24 Apr 2024.
Expression of PDCD1 in breast cancer - the human protein atlas. [cited 26 Jan 2023]. Available: https://www.proteinatlas.org/ENSG00000188389-PDCD1/pathology/breast+cancer . Accessed 24 Apr 2024.
Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7: e51862. https://doi.org/10.1371/journal.pone.0051862 .
doi: 10.1371/journal.pone.0051862
pubmed: 23251644
pmcid: 3522617
UCSC Xena. [cited 30 Apr 2024]. Available: https://xenabrowser.net/datapages/?dataset=TCGA-BRCA.htseq_fpkm.tsv&host=https://gdc.xenahubs.net&removeHub=https://xena.treehouse.gi.ucsc.edu:443 . Accessed 24 Apr 2024.
Zheng C, Wang J, Zhang J, Hou S, Zheng Y, Wang Q. Myelin and lymphocyte protein 2 regulates cell proliferation and metastasis through the Notch pathway in prostate adenocarcinoma. Transl Androl Urol. 2021;10:2067–77. https://doi.org/10.21037/tau-21-244 .
doi: 10.21037/tau-21-244
pubmed: 34159087
pmcid: 8185687
Bhandari A, Shen Y, Sindan N, Xia E, Gautam B, Lv S, et al. MAL2 promotes proliferation, migration, and invasion through regulating epithelial-mesenchymal transition in breast cancer cell lines. Biochem Biophys Res Commun. 2018;504:434–9. https://doi.org/10.1016/j.bbrc.2018.08.187 .
doi: 10.1016/j.bbrc.2018.08.187
pubmed: 30195491
Fan Y, He S. The characteristics of tumor microenvironment in triple negative breast cancer. Cancer Manag Res. 2022;14:1–17. https://doi.org/10.2147/cmar.s316700 .
doi: 10.2147/cmar.s316700
pubmed: 35018117
pmcid: 8740624
Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, Thiery J-P, et al. New insights into the role of EMT in tumor immune escape. Mol Oncol. 2017;11:824–46. https://doi.org/10.1002/1878-0261.12093 .
doi: 10.1002/1878-0261.12093
pubmed: 28614624
pmcid: 5496499
Xu D, Li J, Li R, Lan T, Xiao C, Gong P. PD-L1 expression is regulated by NF-κB during EMT signaling in gastric carcinoma. Onco Targets Ther. 2019;12:10099–105. https://doi.org/10.2147/ott.s224053 .
doi: 10.2147/ott.s224053
pubmed: 31819504
pmcid: 6883928
Zhang L, Xu L-J, Zhu J, Li J, Xue B-X, Gao J, et al. ATM-JAK-PD-L1 signaling pathway inhibition decreases EMT and metastasis of androgen-independent prostate cancer. Mol Med Rep. 2018;17:7045–54. https://doi.org/10.3892/mmr.2018.8781 .
doi: 10.3892/mmr.2018.8781
pubmed: 29568923
pmcid: 5928660
Quan Z, Yang Y, Zheng H, Zhan Y, Luo J, Ning Y, et al. Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer. J Cancer. 2022;13:3434–43. https://doi.org/10.7150/jca.77619 .
doi: 10.7150/jca.77619
pubmed: 36313041
pmcid: 9608206
Oner G, Önder S, Karatay H, Ak N, Tükenmez M, Müslümanoğlu M, et al. Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. World J Surg Oncol. 2021;19:264. https://doi.org/10.1186/s12957-021-02361-9 .
doi: 10.1186/s12957-021-02361-9
pubmed: 34474671
pmcid: 8414710
Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6:74. https://doi.org/10.1186/1756-8722-6-74 .
doi: 10.1186/1756-8722-6-74
pubmed: 24283718
pmcid: 3851976